Formulation, characterisation, and biocompatibility assessment of rifampicin-loaded poly(d,l-lactide-co-glycolide) composites for local treatment of orthopaedic and wound infections
View/ Open
Seaton_et_al_Pharmaceutics (3.516Mb)
Download
Publication date
2024-11Rights
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
2024-11-12
Metadata
Show full item recordAbstract
Background/Objectives: The escalating challenge of antimicrobial resistance (AMR) necessitates the development of targeted antibiotic delivery platforms, minimising systemic administration. Polymer-based drug delivery emerges as a promising solution, ensuring sustained release and prolonged efficacy of bioactive compounds, ensuring long-term efficacy. Methods: This study focuses on encapsulating rifampicin (RIF), a key antibiotic for orthopaedic and wound-related infections, within Poly(d,l-lactide-co-glycolide) (PLGA), a biodegradable polymer, through solvent casting, to formulate a PLGA-RIF composite membrane. Comprehensive characterisation, employing Fourier-transformed infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), thermal analysis and X-ray Diffraction (XRD), confirmed the integrity of both the starting and produced materials. UV-Vis spectroscopy revealed a controlled drug release profile over 21 days in various media, with the chosen media influencing the drug release, notably the tryptic soya broth (TSB) caused the highest release. The quantitative assessment of the antimicrobial efficacy of the developed PLGA-RIF composite was conducted by measuring the size of the inhibition zones against both Gram-negative and Gram-positive bacteria. Results: The results confirmed the composite’s potential as a robust antibacterial biomaterial, demonstrating a rapid and effective antibacterial response. Cytocompatibility tests incorporated human fibroblast and osteoblast-like cell lines and demonstrated that the RIF:PLGA (1:8) formulation maintained eukaryotic cell viability, indicating the composite’s potential for targeted medical applications in combating bacterial infections with minimal systemic impact. Conclusions: This study presents the significance of investigating drug release within appropriate and relevant physiological media. A key novelty of this work therefore lies in the exploration of drug release dynamics across different media, allowing for a comprehensive understanding of how varying physiological conditions may influence drug release and its effect on biological responses.Version
Published versionCitation
Singhal M, Seaton C, Surtees A et al (2024) Formulation, characterisation, and biocompatibility assessment of rifampicin-loaded poly(d,l-lactide-co-glycolide) composites for local treatment of orthopaedic and wound infections. Pharmaceutics. 16(11): 1467.Link to Version of Record
https://doi.org/10.3390/pharmaceutics16111467Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.3390/pharmaceutics16111467